Where I see patients (1)
My reviews
Selected research
- 
							Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
							Blood advances
 - 
							Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
							Cancer medicine
 - 
							A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
							Blood advances
 
Clinical trials
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Tra...
The arm with the largest mean change in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) from baseline to day 90. The Wilcoxon rank-sum test will be used to compare change in FACT-BMT between arms, and thi...
Recruiting
Contact me
- Request appointment
 - Refer a patient
 - (415) 353-2421
 
					
				
														
														
														
														
														
				
			
4.9